Proglumide sodium salt

Key Product Details

Product Description

Proglumide sodium salt is a non-selective cholecystokinin (CCK) antagonist. Inhibits CCK-stimulated amylase secretion and prevents CCK-induced 2-deoxyglucose uptake in mouse pancreatic acini. Blocks growth of HT29 colon carcinoma cells in response to gastrin 17 treatment. Orally active.

Product Specifications for Proglumide sodium salt

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Proglumide sodium salt

The following data is based on the product molecular weight 356.39.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.81 mL	14.03 mL	28.06 mL
5 mM	0.56 mL	2.81 mL	5.61 mL
10 mM	0.28 mL	1.40 mL	2.81 mL
50 mM	0.06 mL	0.28 mL	0.56 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 34 publications citing the usage of this product.

• Mauss Effects of gastrin, proglumide, loxiglumide and L-365,260 on growth of human colon carcinoma cells. Anticancer Res. 1994 PMID: 8166452
• Hahne Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists. Proc.Natl.Acad.Sci.U.S.A. 1981 PMID: 6171817
• Iwamoto In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini. Gastroenterol.Jpn. 1984 PMID: 6202584

Product Documents for Proglumide sodium salt